Poor specificity of fasting plasma glucose cut-off values in ruling out glucose intolerance: The complementary usefulness of OGTT

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 2, 2007, Pages 112-117

  Sainaghi, P P ^a   Castello, L ^a   Limoncini, A M ^a   Bergamasco, L ^a   Bartoli, E ^a,b   Schianca, G P C ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Università del Piemonte Orientale   (Italy)

Author keywords

Diagnosis; Glucose intolerance; OGTT

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FALSE NEGATIVE RESULT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33947096071     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-949151     Document Type: Article

References (31)

1. Alberti G, Zimmet PZ, Shaw J, Bloomgarden Z, Kaufman F, Silink M: Consensus Workshop Group. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004; 27: 1798-1811
2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
3. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD et al: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999; 354: 622-625
4. Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E: The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 2003; 26: 1333-1337
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077
6. Crepaldi G, Belfiore F, Bosello O, Caviezel F, Contaldo F, Enzi C et al: Italian Consensus Conference; overweight, obesity and health (ICC S.O.S. 1991). Recenti Prog Med 1991; 82: 417-434
7. Davidson MB, Landsman PB, Alexander CM: Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 2003; 26: 3329-3330
8. Davidson MB: Counterpoint: the oral glucose tolerance test is superfluous. Diabetes Care 2002; 25: 1883-1885
9. DECODE Study Group, European Diabetes Epidemiology Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-696
10. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38: 387-395
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
13. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J et al: The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes 1985; 34: 580-588
14. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-490
15. Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM: Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004; 53: 1549-1555
16. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167
17. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: American Heart Association; National Heart, Lung, and Blood Institute: definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438
18. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C: Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212-218
19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
20. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U: Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72: 1150-1162
21. Kuhl J, Hilding A, Ostenson CG, Grill V, Efendic S, Bavenholm P: Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity. Diabetologia 2005; 48: 35-40
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057
23. Piche ME, Arcand-Bosse JF, Despres JP, Perusse L, Lemieux S, Weisnagel SJ: What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 2004; 27: 2470-2477
24. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
25. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-472
26. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-2681
27. Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K et al: Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004; 27: 1728-1734
28. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T et al: Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-1462
29. Tuomilehto J: Point: a glucose tolerance test is important for clinical practice. Diabetes Care 2002; 25: 1880-1882
30. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723
31. Weyer C, Tataranni PA, Bogardus C, Pratley RE: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24: 89-94